BioNTech Results Presentation Deck

Fix Vac I BNT116: Phase 1 Trial in Patients with Advanced NSCLC 18 Advanced or metastatic non-small-cell lung cancer Key endpoints Primary: Safety and tolerability Secondary: Clinical activity NSCLC, non-small-cell lung cancer; TPS, tumor proportion score *Regeneron's LibtayoⓇ Clinicaltrials.gov: NCT05142189. Cohort 1: BNT116 monotherapy Cohort 2: BNT116 + cemiplim ab* After progression on prior PD-1 inhibitor; PD-L1 expression: TPS >50% Cohort 3: BNT116 + docetaxel After prior platinum-based therapy and PD-1 inhibitor (if eligible) Cohort 4: BNT116 + cemiplim ab* Patients not eligible for chemotherapy; PD-L1 expression: TPS ≥1% Status FPD in July 2022 BIONTECH

View entire presentation